These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 7493197)

  • 1. Understanding the essentials of economic evaluation.
    Schmid GP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S6-13. PubMed ID: 7493197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and assessment of cost-effectiveness studies in AIDS populations.
    Simpson KN
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S28-32. PubMed ID: 7493196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation for ophthalmologists.
    Kuper H; Jofre-Bonet M; Gilbert C
    Ophthalmic Epidemiol; 2006 Dec; 13(6):393-401. PubMed ID: 17169853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. It is money that matters: decision analysis and cost-effectiveness analysis.
    Kocher MS; Henley MB
    Clin Orthop Relat Res; 2003 Aug; (413):106-16. PubMed ID: 12897601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
    Weintraub WS
    J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation in critical care medicine.
    Cox HL; Laupland KB; Manns BJ
    J Crit Care; 2006 Jun; 21(2):117-24. PubMed ID: 16769454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficiency-based healthcare. General concepts on economic evaluation of healthcare interventions].
    Catalá-López F
    Enferm Clin; 2009; 19(1):35-42. PubMed ID: 19233020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific considerations for cost-effectiveness studies in AIDS.
    Bozzette SA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S23-7. PubMed ID: 7493195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
    Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
    J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health economic methods: cost-minimization, cost-effectiveness, cost-utility, and cost-benefit evaluations.
    Higgins AM; Harris AH
    Crit Care Clin; 2012 Jan; 28(1):11-24, v. PubMed ID: 22123096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presentation of economic evaluation results.
    Chaikledkaew U; Teerawattananon Y
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S66-73. PubMed ID: 19253489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Working toward a common currency: is standardization of cost-effectiveness analysis possible?
    Luce BR
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S19-22. PubMed ID: 7493194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Decision analytic modeling and their impact on health care decision making].
    Inotai A; Kaló Z; Mészáros A
    Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of early intervention services.
    McCrone P; Knapp M
    Br J Psychiatry Suppl; 2007 Dec; 51():s19-22. PubMed ID: 18055933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation in the health sector: concepts and methods].
    Contandriopoulos AP; Champagne F; Denis JL; Avargues MC
    Rev Epidemiol Sante Publique; 2000 Dec; 48(6):517-39. PubMed ID: 11148425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodological design for economic evaluation in Public Access Defibrillation (PAD) trial.
    Nichol G; Wells GA; Kuntz K; Feeny D; Longstreth W; Mahoney B; Mann C; Lucas R; Henry M; Huszti E; Birnbaum A
    Am Heart J; 2005 Aug; 150(2):202-8. PubMed ID: 16086918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of cost effectiveness in primary health care].
    Busse R; Graf von der Schulenburg JM; Drummond M
    Z Arztl Fortbild Qualitatssich; 1997 Aug; 91(5):447-55. PubMed ID: 9377699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness: from whose perspective?
    Hillman AL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S14-8. PubMed ID: 7493193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?
    Phillips KA; Hotlgrave DR
    Am J Prev Med; 1997; 13(1):18-25. PubMed ID: 9037338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.